Tuesday's Health Winners & Losers

Updated from 11:59 a.m. EDT

Shares of Adolor (ADLR Quote) were among the day's health care losers, plummeting 58.7% after the company halted a clinical test for its constipation treatment drug Entereg. The move led to several downgrades from broker firms. Recently, Adolor fell by $5.12 to $3.60.

On the other hand, Pharmacopeia Drug (PCOP Quote) was higher after the company said a phase I trial for its hypertension and diabetic nephropathy drug candidate yielded positive results. A phase II trial is expected to begin in the first half of 2008. Pharmacopeia climbed 46 cents, or 7.7%, to $6.40.

Renovis (RNVS Quote) also gained ground, at one point jumping 18.4%. Earlier, the company said it will extend a collaboration deal with Pfizer (PFE Quote) through June 30, 2008. Shares of Renovis closed up 15 cents, or 3.8%, to $4.12.

Other health care winners included Incyte Corporation (INCY Quote), which was up 8% to $7.58. Theravance (THRX Quote) gained 4.6% to $31.88, and Elan (ELN Quote), which was adding 2.3% earlier in the day, was up 0.4% to to $14.53.

Among decliners, Antigenics (AGEN Quote) slid 17.2% to $3.57. Cell Genesys (CEGE Quote) slipped 11.4% to $6.08. Dendreon (DNDN Quote), which has tripled over the last week, shed 6.1% to $22.15.